Prelude Therapeutics (PRLD) Common Equity (2019 - 2026)

Prelude Therapeutics has reported Common Equity for 8 years, with the latest figure at $60.2 million in Q1 2026.

• Quarterly Common Equity fell 41.67% year-over-year to $60.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.2 million (down 41.67% YoY) and the FY2025 annual result came in at $68.6 million, down 47.79% from the prior year.
• Common Equity declined to $60.2 million in Q1 2026 per PRLD's latest filing, from $68.6 million in the prior quarter.
• Over five years, Common Equity peaked at $262.1 million in Q2 2023 and troughed at $58.5 million in Q3 2025.
• A 5-year average of $169.1 million and a median of $182.3 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity climbed 21.31% in 2023, then plunged 62.58% in 2025.
• Over 5 years, Common Equity stood at $195.4 million in 2022, then advanced by 21.31% to $237.1 million in 2023, then tumbled by 44.55% to $131.5 million in 2024, then tumbled by 47.79% to $68.6 million in 2025, then declined by 12.32% to $60.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $60.2 million, $68.6 million, and $58.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.